Chime Biologics, a CDMO, announced that it has established 3-way strategic cooperation with Leads Biolabs and BeiGene to accelerate LBL-007 mAb development and manufacturing for speedy clinical advancement.
LBL-007 is a novel antibody targeting the LAG-3 pathway developed independently by Leads Biolabs. The phase I clinical trial data of LBL-007 in patients with later-stage solid tumors have been announced at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO).
Previously, Leads Biolabs and BeiGene reached an authorization and cooperation agreement. Leads Biolabs grants LBL-007 exclusive global development and production license to BeiGene, as well as a commercial manufacturing license outside China.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special
offers from Pharmaceutical Outsourcing – all delivered right to your inbox! Sign up now!